THEM4 and head and neck squamous cell carcinoma: Moreover, if validated in further studies including in vivo and clinical trial, a CTMP-targeting agent partnered with an existing anticancer modality could be a novel tactic to overcome drug resistance and ultimately improve HNSCC outcomes.